ES2173945T3 - Uso de antagonistas de aldosterona para inhibir fibrosis miocardiaca. - Google Patents

Uso de antagonistas de aldosterona para inhibir fibrosis miocardiaca.

Info

Publication number
ES2173945T3
ES2173945T3 ES95903131T ES95903131T ES2173945T3 ES 2173945 T3 ES2173945 T3 ES 2173945T3 ES 95903131 T ES95903131 T ES 95903131T ES 95903131 T ES95903131 T ES 95903131T ES 2173945 T3 ES2173945 T3 ES 2173945T3
Authority
ES
Spain
Prior art keywords
inhibit
miocardiac
fibrosis
aldosterone antagonists
aldosterone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95903131T
Other languages
English (en)
Inventor
Karl T Weber
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Missouri System
Original Assignee
University of Missouri System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Missouri System filed Critical University of Missouri System
Application granted granted Critical
Publication of ES2173945T3 publication Critical patent/ES2173945T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

ESTA INVENCION DESCRIBE UN METODO DE UTILIZACION DE UN ANTAGONISTA DE ALDOESTERONA COMO ESPIRONOLACTONA Y EPOXIMEXRENONA, EN UNA DOSIFICACION QUE NO INTERRUMPE EL EQUILIBRIO DE ELECTROLITO Y RETENCION DE AGUA NORMAL DE UN PACIENTE, PARA INHIBIR FIBROSIS MIOCARDIACA, INCLUYENDO HIPERTROFIA DEL VENTRICULO IZQUIERDO (LVH).
ES95903131T 1993-12-02 1994-12-01 Uso de antagonistas de aldosterona para inhibir fibrosis miocardiaca. Expired - Lifetime ES2173945T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/160,236 US5529992A (en) 1992-04-21 1993-12-02 Method for inhibiting myocardial fibrosis by administering an aldosterone antagonist which suppresses aldoster one receptors

Publications (1)

Publication Number Publication Date
ES2173945T3 true ES2173945T3 (es) 2002-11-01

Family

ID=22576080

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95903131T Expired - Lifetime ES2173945T3 (es) 1993-12-02 1994-12-01 Uso de antagonistas de aldosterona para inhibir fibrosis miocardiaca.

Country Status (9)

Country Link
US (3) US5529992A (es)
EP (1) EP0730458B1 (es)
JP (1) JP2916267B2 (es)
AT (1) ATE214607T1 (es)
AU (1) AU703147B2 (es)
CA (1) CA2177848A1 (es)
DE (1) DE69430209T2 (es)
ES (1) ES2173945T3 (es)
WO (1) WO1995015166A1 (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6150347A (en) * 1992-04-21 2000-11-21 The Curators Of The University Of Missouri Use of aldosterone antagonists to inhibit myocardial fibrosis
US6008210A (en) * 1992-04-21 1999-12-28 Weber; Karl T. Use of aldosterone antagonists to inhibit myocardial fibrosis
US6245755B1 (en) 1992-04-21 2001-06-12 Curators Of The Unversity Of Missouri Use of aldosterone antagonists to inhibit myocardial fibrosis
WO1996024358A1 (en) * 1995-02-10 1996-08-15 G.D. Searle & Co. Use of low dose amount of spironolactone for treatment of cardiovascular disease
DE69617235T2 (de) * 1995-06-07 2002-07-25 G.D. Searle & Co., Chicago Epoxysteroide aldosteronantagonist und angiotensin ii rezeptor antagonist kombinationstherapie zur behandlung von congestivem herzversagen
AU5349400A (en) * 1995-06-07 2000-10-26 G.D. Searle & Co. Epoxy-steroidal aldosterone antagonist and angiotensin II antagonist combination therapy for the treatment of congestive heart failure
WO1996040255A2 (en) 1995-06-07 1996-12-19 G.D. Searle & Co. Method to treat cardiofibrosis with a combination therapy of an angiotensin ii antagonist and an epoxy-steroidal aldosterone antagonist
EP0831911B1 (en) * 1995-06-07 2002-04-17 G.D. Searle & Co. Spironolactone and angiotensin ii antagonist combination therapy for treatment of congestive heart failure
AU5982296A (en) * 1995-06-07 1996-12-30 G.D. Searle & Co. Method to treat cardiofibrosis with a combination of an angi otensin ii antagonist and spironolactone
UA74141C2 (uk) 1998-12-09 2005-11-15 Дж.Д. Сірл Енд Ко. Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти)
US6211217B1 (en) 1999-03-16 2001-04-03 Novartis Ag Method for reducing pericardial fibrosis and adhesion formation
JP2003513913A (ja) * 1999-11-09 2003-04-15 ファルマシア コーポレイション 血管傷害に起因する病的変化をアルドステロンアンタゴニストで治療、阻害または予防する方法
DE60019741T2 (de) * 1999-12-08 2006-03-02 Pharmacia Corp., Chicago Nanopartikelzusammensetzungen enthaltend eplerenon
EP1527782A1 (en) * 1999-12-08 2005-05-04 Pharmacia Corporation Nanoparticulate eplerenone compositions
JP3566940B2 (ja) * 2000-04-18 2004-09-15 古河電気工業株式会社 アレイ導波路回折格子型光合分波器
US20020132001A1 (en) * 2000-05-11 2002-09-19 Garthwaite Susan M. Aldosterone antagonist composition for release during aldosterone acrophase
AU1604001A (en) * 2000-06-13 2001-12-24 Pharmacia Corp Use of an aldosterone antagonist for the treatment or prohpylaxis of aldosterone-mediated pathogenic effects
US6716829B2 (en) 2000-07-27 2004-04-06 Pharmacia Corporation Aldosterone antagonist and cyclooxygenase-2 inhibitor combination therapy to prevent or treat inflammation-related cardiovascular disorders
WO2002009683A2 (en) * 2000-07-27 2002-02-07 Pharmacia Corporation Aldosterone blocker therapy to prevent or treat inflammation-related disorders
DE60114027T2 (de) * 2000-08-28 2006-07-13 Pharmacia Corp. Verwendung von einem aldosteron-rezeptor-antagonisten zur verbesserung der kognitiven funktion
ITMI20010821A1 (it) * 2001-04-17 2002-10-17 Gienne Pharma S P A Impiego di composti derivati dallo spirolattone per inibire l'azione pro-fibrigenetica delle cellule stellate epatiche e delle cellule musco
JP2005516914A (ja) 2001-12-12 2005-06-09 ファルマシア・コーポレーション エポキシ−ステロイド系アルドステロン受容体アンタゴニストで眼病を治療する方法
AU2002368473A1 (en) * 2002-01-25 2004-09-09 Pharmacia Corporation Aldosterone blocker therapy to prevent or treat inflammation-related disorders
KR20040096540A (ko) * 2002-01-30 2004-11-16 파마시아 코포레이션 심혈관 질환의 예방 또는 치료를 위한 알도스테론 수용체길항제 및 알파-아드레날린성 조절제 복합 요법
CN1668312A (zh) * 2002-05-13 2005-09-14 洛杉矶儿童医院 疤痕疙瘩和其它的皮肤或内部的创伤或损伤中异常疤痕形成的处理和抑制
US20040102375A1 (en) * 2002-05-15 2004-05-27 Massachusetts Institute Of Technology Methods to overcome inhibition of growth cone translocation
ATE335744T1 (de) * 2002-08-07 2006-09-15 Novartis Pharma Gmbh Organische verbindungen als mittel zur behandlung von aldosteronbedingten zuständen
JP2005536536A (ja) * 2002-08-23 2005-12-02 ファルマシア コーポレイション アルドステロンブロッカーによるマトリックスメタロプロテイナーゼ（ｍｍｐ）活性のモジュレーション
US7786101B2 (en) 2002-11-05 2010-08-31 Bayer Schering Pharma Ag Cardiovascular protection using anti-aldosteronic progestins
AU2003278434A1 (en) * 2002-11-05 2004-06-07 Schering Aktiengesellschaft Cardiovascular protection using anti-aldosteronic progestins
PT1565463E (pt) * 2002-11-18 2008-09-10 Novartis Ag Derivados de imidazo[1,5-a]piridina e métodos para tratar doenças mediadas pela aldosterona
US8569277B2 (en) 2004-08-11 2013-10-29 Palo Alto Investors Methods of treating a subject for a condition
WO2007097951A2 (en) * 2006-02-17 2007-08-30 Nitromed, Inc. Methods using hydralazine compounds and isosorbide dinitrate or isosorbide mononitrate
KR20090020580A (ko) * 2006-05-26 2009-02-26 노파르티스 아게 알도스테론 신타제 및/또는 11β-히드록실라제 억제제
WO2008021666A2 (en) * 2006-08-18 2008-02-21 Morton Grove Pharmaceuticals, Inc. Stable liquid levetiracetam compositions and methods
RU2009110442A (ru) * 2006-08-25 2010-09-27 Новартис АГ (CH) Конденсированные производные имидазола для лечения нарушений, опосредованных альдостеронсинтазой, и/или 11-бета-гидроксилазой, и/или ароматазой
WO2009097893A1 (en) * 2008-02-04 2009-08-13 Proyecto De Biomedicina Cima, S.L. Methods for the treatment of cardiac disease associated to myocardial fibrosis using an inhibitor of pcp
ES2848348T3 (es) * 2014-05-16 2021-08-06 Cumberland Pharmaceuticals Inc Composiciones y métodos de tratamiento con ifetroban de la fibrosis cardíaca

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4003996A (en) * 1974-09-09 1977-01-18 G. D. Searle & Co. Spirolactone for inhibiting the cardiotoxic effects of adriamycin

Also Published As

Publication number Publication date
JP2916267B2 (ja) 1999-07-05
DE69430209D1 (de) 2002-04-25
EP0730458B1 (en) 2002-03-20
US5668124A (en) 1997-09-16
JPH09508354A (ja) 1997-08-26
US5668125A (en) 1997-09-16
AU1210695A (en) 1995-06-19
US5529992A (en) 1996-06-25
CA2177848A1 (en) 1995-06-08
ATE214607T1 (de) 2002-04-15
DE69430209T2 (de) 2002-12-12
EP0730458A1 (en) 1996-09-11
WO1995015166A1 (en) 1995-06-08
AU703147B2 (en) 1999-03-18

Similar Documents

Publication Publication Date Title
ES2173945T3 (es) Uso de antagonistas de aldosterona para inhibir fibrosis miocardiaca.
CL2004000119A1 (es) Composicion farmaceutica que comprende un agonista/antagonista de estrogenos definido y un secretagogo de la hormona del crecimiento, util para tratar una condicion que se presenta con una masa osea reducida.
ES2144989T1 (es) Utilizacion de un copolimero de acido metacrilico de tipo c como agente, o co-agente, de disgregacion.
PT735882E (pt) Combinacao contraceptiva contendo antagonistas de progesterona e um progestogeno
ES2133130B1 (es) Nueva formulacion de budesonida, su uso y recipiente que la contiene.
BR0101332A (pt) Formulação oftálmica tópica na forma de uma solução aquosa, e, uso de uma ciclosporina em associação com ácido hialurÈnico ou um de seus sais e com polisorbato 80
ES2185817T3 (es) Formas de dosificacion farmaceutica oral que comprenden un inhibidor de las bombas de protones y un agente antiacido o alginato.
DE60124240D1 (de) Pyrophosphate zur erhöhung der zellfunktion durch schutz von muscarinrezeptoren
ES2182357T3 (es) Nueva utilizacion de budesonide y formoterol.
HUP9701560A1 (hu) "Olaj a vízben"típusú topikális alkalmazású folyékony emulzió készítmény
BR9915134A (pt) Co-terapia e terapia combinada para o tratamento de distúrbio cardiovascular em um indivìduo, e, composição
ES2190205T3 (es) Combinacion para el tratamiento de la dependencia del alcohol que contiene un antagonista opioide y un modulador del complejo receptor de nmda.
DE69932510D1 (de) Vaskularisierungsinhibitoren
ECSP045025A (es) Combinación de opioides seleccionados con antagonistas muscarnicos para el tratamiento de la incontinencia urinaria
CY1104971T1 (el) Παρασκευασμα αποϊνιδοτιδιου και g-csf και η χρηση του για να κινητοποιει αιμοποιητικους προγονους
AR040130A1 (es) Esteres de etonogestrel, su uso como anticopceptivo y para el tratamiento de desordenes ginecologicos
PT706385E (pt) Utilizacao de isovaleramida como agente ansiolitico suave e como agente sedativo suave
UY28007A1 (es) Tratamiento terapeutico
CO5200833A1 (es) Regimenes de dosificacion para lasofoxifeno
UY28017A1 (es) Tratamiento terapéutico
BR0008952A (pt) Composição de preparação de iodo
UY24063A1 (es) Empleo de concentrados con contenido de factor von willebrand (vwf) como terapia de combinacion en la terapia con antitromboticos y fibrinoliticos
AR027287A1 (es) Gonadotrofina
CL2004001317A1 (es) Composicion farmaceutica que comprende el antagonista de receptores de progesterona 11b-(4-acetilfenil)-17b-hidroxi-17 alfa-(1,1,2,2,2-pentafluoroetil)-estra-4,9-dien-3-ona y un antiestrogeno puro; y su uso para tratar una enfermedad dependiente de h
FR2797399B1 (fr) Utilisation de la cyamemazine dans le traitement du sevrage aux benzodiazepines

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 730458

Country of ref document: ES